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EPIGENETIC EVENTS SUGGEST A DISTINCT MOLECULAR PATHOGENESIS IN
BRAF-ASSOCIATED PAPILLARY THYROID CANCER.
Ogechukwu Eze, Lee Starker, William Long, Robert Udelsman, Peyman Björklund, and
Tobias Carling. Department of Surgery, Yale University School of Medicine, New
Haven, CT, USA.
Papillary thyroid cancer (PTC) associated with a somatic V-raf murine sarcoma viral
oncogene homolog B1 (BRAF) V600E mutation has been associated with a more
aggressive phenotype (i.e. extrathyroidal extension, lymph node metastasis, high TNM
stage and recurrence) than those with wildtype (WT) BRAF. The underlying molecular
mechanism for this association is incompletely clarified. Epigenetic alterations, such as
DNA methylation participate with genetic abnormalities to cause altered patterns of gene
expression and/or function leading to oncogenesis. Using a quantitative, genome-wide
approach to evaluate the PTC DNA methylome, we identified a distinct DNA
methylation profile in BRAF-associated PTC. This represents the first, unbiased,
systematic, quantitative genome-wide evaluation of DNA methylation alterations in PTC.

A distinct DNA methylation profile was noted in BRAF V600E PTC versus BRAF WT
PTC. Twenty-four genes were significantly hypermethylated in BRAF V600E PTC
versus BRAF WT (p<0.005 for all). Genes frequently and significantly hypermethylated
in BRAF V600E PTC included those involved in transcriptional regulation and cell cycle
control such as CDKN2B/p15, RASSF1A and CD6. 25 BRAF V600E PTC and 25 BRAF
WT PTC were used for validation of the methylation profile of RASSF1 and analysis of
its gene expression. One of two CpG islands in the RASSF1A promoter was differentially
methylated with an average of 73% and 8% methylation in BRAF V600E PTC and
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BRAF WT PTC respectively. In addition, 92% (n=23) of the BRAF V600E tumors were
hypermethylated at this CpG island, compared to 12% (n=3) of the BRAF WT tumors.
Expression of RASSF1A was decreased in BRAF V600E PTC relative to expression in
BRAF WT PTC.

The DNA methylation profile of PTC correlates with BRAF mutational status,
underscoring its importance in PTC development. The molecular mechanism of the more
aggressive phenotype of BRAF V600E PTC may be related to aberrant DNA methylation
of genes involved in transcriptional and cell cycle control. Functional studies assessing
the effect of azanucleoside, a demethylating agent on RASSF1A gene expression may
further determine a cause-effect relationship. Furthermore, conducting such functional
experiments in BRAF V600E PTC and BRAF WT PTC cell cultures would be critical in
assessing the possibility of clinically applying a demethylating agent to treatment of
aggressive, BRAF V600E PTC.
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INTRODUCTION

Thyroid carcinoma is the most common endocrine malignancy. Papillary thyroid
cancer (PTC) accounts for over 90% of thyroid malignancies1. With improved diagnostic
techniques, papillary thyroid carcinoma is identified much more frequently than in the
past2. Currently, the majority of patients present with a thyroid nodule and are often
asymptomatic. Symptomatic patients, however, may present with concomitant vocal cord
dysfunction or subglottic/tracheal mass, recurrent disease in the central compartment,
symptomatic disease with voice changes, dyspnea, hemoptysis or dysphagia, and finally,
patients with documented invasive disease based on pre-operative imaging3. More
papillary thyroid cancers are diagnosed as microcarcinomas, therefore molecular methods
of detecting aggressive disease will aid in treatment planning.

Genetic Alterations in Papillary Thyroid Cancer
The majority of genetic alterations in thyroid cancer exert their oncogenic actions
at least partially through the activation of the RAS/mitogen-activated protein
kinase/Extracellular signal-regulated protein kinase (MAPK/ERK) pathway. Constitutive
activation of the MAPK/ERK pathway leads to tumorigenesis by upregulating cell
division and proliferation4. Activation of this pathway is a common and important
mechanism in the genesis and progression of human cancers. When constitutively
activated, the MAPK/ERK pathway leads to tumorigenesis4. Alterations of RET/PTC,
BRAF and RAS genes are linked to papillary thyroid tumorigenesis.
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The RAS/mitogen-activated protein kinase (MAPK)/Extracellular signal-regulated
protein kinase (ERK) pathway
The mitogen-activated protein kinases are proline-targeted serine/threonine
kinases involved in the RAS/mitogen-activated protein kinase (MAPK)/Extracellular
signal-regulated protein kinase (ERK) signal transduction pathways that regulate nuclear
gene transcription in response to changes in the cellular environment (Turjanski, 2007).
The MAPK/ERK pathway is activated by a GTP-bound active RAS protein,
which is activated by binding of an extracellular growth factor to a growth factor receptor
in the cell membrane causing receptor phosphorylation and interaction with a nucleotide
exchange factor, SOS, and inactive GDP-bound RAS. Activation of RAS results in a
conformational change that allows it to interact with RAF, a serine-threonine kinase and
bring it to the plasma membrane. RAF phosphorylates and activates MAPK/ERK kinase,
which in turn phosphorylates ERK kinase. Phosphorylated ERK translocates to the
nucleus, targeting transcription factors.
Activation of the RAS/MAPK/ERK kinase signal transduction pathway is
involved in transcription of nuclear oncogenes such as MYC and FOS, and cell cycle
components such as cyclin D1. This pathway controls cellular functions involved in
tumorigenesis, including cell proliferation, differentiation, migration and apoptosis 5-7.
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Figure 1. The mitogen-activated protein kinase (MAPK)/Extracellular signal-regulated
protein kinase (ERK) pathway
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RET/PTC
RET proto-oncogene encodes a cell membrane receptor tyrosine kinase. Ligands
of the kinase are of the glial-cell line-derived neurotrophic factor (GDNF) family which
cause the receptors to dimerize upon binding, leading to auto-phosphorylation of tyrosine
residues and initiation of the MAPK/ERK pathway signaling cascade8. High expression
of RET in parafollicular C-cells of the thyroid gland are consistent with its role in
development of neural crest-derived cell lineages. This high expression of RET does not
occur in thyroid follicular cells, however, RET activation in these cells occurs by fusion
of the 3’ tyrosine domain of RET to the 5’ portion of constitutively expressed genes.
The most common RET/PTC rearrangements seen in PTC are RET/PTC1 (fusion
with H4 gene) and RET/PTC3 (fusion with NCOA4 gene). Prevalence of RET/PTC
rearrangements in PTC is greatest in populations exposed to radiation (60–70%). In the
general population, the prevalence is higher in children6. Activation of RET/PTC results
in downregulation of thyroglobulin and sodium iodide importer genes, which are thyroid
specific, and cell differentiation. Wildtype RET/PTC and truncated forms of RET/PTC
activate a number of other pathways, including the PI3K/AKT pathway, contributing to
its biological activity9.

BRAF
Mutations of BRAF, a serine-threonine kinase and downstream signaling
molecule of RAS and RET, are potent activators of the MAPK/ERK pathway4,10. These
missense mutations of the BRAF gene, located on chromosome 7, occur in the kinase
domain with the T1799A transversion mutation resulting in a single amino acid
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substitution of valine to glutamic acid (V600E) accounting for 80-90% of BRAF
activating mutations6,11. The V600E mutation is thought to mimic phosphorylation in the
activation segment of BRAF by inserting a negatively charged residue adjacent to an
activating phosphorylation site4.
BRAF V600E occurs as a sporadic mutation in thyroid cancer11,12 and is restricted
to papillary and anaplastic or poorly differentiated carcinomas13. Prevalence of the
mutation is reported in papillary thyroid cancer at 35-40%, with a significantly higher
prevalence in males than females11. The rate of BRAF mutation in PTC is the second
highest to that in melanomas (60%) and is much higher than other cancers such as
colorectal adenocarcinomas (5–10%) and lung cancers (1.8%)11. BRAF V600E correlates
with poorer clinicopathologic outcomes defined as extrathyroidal extension, lymph node
metastasis, and advanced tumor grade (III/IV) at presentation, and is prognostic of tumor
recurrence14,15.
Although not confirmed by similar studies12, 38% of papillary thyroid tumors
showed RET/PTC rearrangement11, contrary to reports that BRAF V600E mutation is
does not occur with RET/PTC or RAS mutations in cancer12. The low oncogenic
potential of both BRAF and RET/PTC1 suggest that both mutations occurring in the
same pathway are not necessarily redundant, but may cooperate in papillary thyroid
tumorigenesis. Indeed, RET/PTC1 and RAS mutations have been shown to
synergistically lead to tumorigenesis11.

RAS
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Activating mutations of the three RAS oncogenes (H-RAS, K-RAS, and N-RAS)
occur in thyroid tumors, however, their prevalence depending on histology of the tumors
has been controversial16. Early studies demonstrated that RAS mutations were more
frequent in follicular tumors than papillary thyroid cancers, in addition to different
patterns of mutations occurring in the two types. Indeed, mutations in up to 50% on
microfollicular adenoma further supported the idea that RAS oncogene activation was an
early event in follicular thyroid tumorigenesis. More recent studies have reported varying
incidences of RAS mutations in thyroid tumors (0-50% in PTC, 0-85% in adenomas, 1462% in FTC, and 0-60% in anaplastic carcinomas). Some investigators find no
correlation between RAS mutation isoforms and tumor pathology, while others report a
higher frequency of mutations in codon61 of H-RAS and N-RAS in FTC and poorly
differentiated carcinomas.
The molecular pathogenesis of PTC thus remains incompletely clarified. With
respect to gene alterations, papillary thyroid cancers have relatively low rates of loss of
heterozygosity, with no specific region displaying a particularly high prevalence when
compared to follicular thyroid cancers17. Like RET, BRAF or RAS mutations, other
molecular alterations are thought to be essential for the induction of papillary thyroid
cancer. Epigenetic events are very likely to contribute to significant variation in gene
expression profiling, phenotypical features, and biologic characteristics seen among
papillary thyroid carcinoma18.

Familial Nonmedullary Thyroid Cancer
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Although mostly sporadic, there is some evidence for a familial form of
nonmedullary thyroid cancer (NMTC), which includes PTC, not associated with known
Mendelian syndromes. Familial nonmedullary thyroid cancer (FNMTC) is thought to
cause a more aggressive disease marked by younger age at presentation, multifocality,
local invasion, lymph node metastasis and tumor recurrence. Linkage analysis data is
limited by the small size and inconsistent inclusion criteria of the studies performed, but
point to a polygenic mode of inheritance in FNMTC. Perhaps the most important result of
these studies is the exclusion of several genes, namely the adenomatous polyposis coli
(APC), phosphate and tensin homolog (PTEN), thyroid-stimulating hormone receptor,
rearranged during transfection (RET), tropomyosin receptor kinase, hepatocyte growth
factor receptor (MET), TRKA, JUNB, and BRAF genes.

Epigenetics mechanisms involved in tumorigenesis
Epigenetic silencing of regulatory genes is part of the global genomic alterations
in cancer that alter pathways relevant to stem cell growth and differentiation. Epigenetic
silencing mechanisms include covalent modifications of chromatin, DNA cytosine
methylation, non-coding RNAs, and nucleosome remodelling19. It has been proposed that
epigenetic abnormalities may play a seminal role in the earliest steps in tumorigenesis2023

. Epigenetic changes may act in concert with genetic changes resulting in

tumorigenesis, because they are mitotically heritable. The high degree of mitotic stability
of silencing plus the progressive nature by which it is achieved makes pathological
silencing of growth controlling, and other genes essential to carcinogenesis.
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Patterns of DNA methylation are linked to gene expression; for example,
methylation in a gene promoter region generally correlates with a silenced gene24. DNA
methylation, the DNA methyltransferase (DNMT) catalyzed addition of methyl group to
cytosine ring is restricted to cytosines that precede a guanosine in the DNA sequence (the
CpG dinucleotide) in humans and other mammals24. The distribution of CpG
dinucleotides in the genome is unusually asymmetric, occurring in small clusters called
“CpG islands”. The CpG islands are often in promoter regions of genes and are usually
unmethylated regardless of the transcriptional state. This highlights the importance of
DNA methylation for gene expression, especially in transcriptional silencing24.
Aberrant DNA methylation plays a strong role in tumorigenesis. Global
hypomethylation of intergenic CpG dinucleotides and regional hypermethylation of CpG
islands in promoter regions are characteristic hallmarks of many cancers23. The impact of
hypermethylation on tumorigenesis is further illustrated by the silencing of multiple
tumor suppressor genes, thereby contributing to the hallmarks of carcinogenesis which
include evading apoptosis (P53, p14ARF, BNIP3, Caspase-8), insensitivity to antigrowth
signals (p16INK4a, miR-124a), sustained angiogenesis (TIMP3, TSP1), limitless
replicative potential (hTERT), and tissue invasion and metastasis (E-cadherin, LIMS2).
Transcriptional silencing is also a result of chromatin compaction due to
convergence of DNA methylation and histone modifications. Methylated DNA recruits
methyl-binding proteins (MBDPs), which have methyl-CpG-binding domains (MBD), to
hypermethylated DNA. MBDPS also associate with histone deacetylases, resulting in
chromatin remodeling and gene silencing. In addition to these mechanisms of silencing,
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histone methyltransferase (HMTs) repress transcription by methylation of lysine 9 of
histone 3 (H3K9) or lysine 27 of histone 3 (H3K27).
The influence of epigenetic events on tumorigenesis is well illustrated the
evolution of colon cancer, in which risk factors for common cancers such as aging and
inflammation are shown to cause expansions in either normal colon epithelial stem cells
or precursor cells derived from them. Epigenetic gatekeepers such as cyclin-dependent
kinase inhibitor 2A (CDKN2A/p16), secreted frizzled-related protein (SFRP), GATAbinding protein 4 and 5 (GATA-4 and -5), and adenomatous polyposis of the colon
(APC) prevent early tumor progression in colon cancer. Normal epigenetic modulation of
these gatekeeper genes allows them to prevent stem/precursor cells from becoming
immortalized during periods of chronic stresses and renewal pressures on cell systems.
APC is a classically mutated tumor suppressor gene in colon cancer, which is also
inactivated by epigenetic mechanisms25. Epigenetic silencing of one allele serves as a
second-hit in Knudson’s hypothesis for tumor suppressor gene inactivation when paired
which mutations on the other allele20.
Like APC, loss of p16 can be epigenetically mediated, permitting expanding cells
to develop genomic instability26,27 and further epigenetic gene-silencing events28. Its loss
is seen in subsets of pre-invasive stages of colon and other cancers28. Finally, GATA-4
and -5 transcription factor genes important for both embryonic gastrointestinal epithelial
development and for maturation in adults are epigenetically silenced in about half of all
the pre-invasive and invasive lesions for colon cancer29. This can hamper differentiation
and promote precursor cell expansion.
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The wingless-type MMTV integration site (Wnt) pathway activation also
illustrates how multiple epigenetic events may act in concert to affect a single-cell
pathway. Inappropriate silencing of these genes leads to abnormal activation of the Wnt
pathway, which plays a canonical role in colon tumorigenesis22. These genes are
independently affected by epigenetic events but result in Wnt activation. Four genes in
the SFRP family encode proteins that antagonize the action of the Wnt ligand at the cell
membrane are hypermethylated simultaneously in the majority of pre-invasive lesions for
colon cancer. Upregulation of the survival protein Sirtuin 1 (SIRT1) also results in Wnt
pathway activation. SIRT1 is upregulated as a result of loss of the transcription factor
hypermethylated in cancer 1 (HIC1) via hypermethylation in early pre-invasive lesions in
colon cancer as well as other types of cancer22. Loss of HIC1 also results in additional
gene silencing events as well as downregulation of tumor protein 53 (p53).
Loss of DNA methylation results in weakening of transcriptional repression in
normally silent regions of the genome resulting in harmful expression of inserted or
normally silenced genes, and loss of functional stability of chromosomes. It has been
established that covalent histone modification is linked to DNA methylation. Cytosine
methylation attracts methylated DNA-binding proteins and histone deacetylases to
methylated CpG islands during chromatin compaction and gene silencing30,31. In addition
to epigenetic modification of transcriptional start sites, there is evidence for more global
changes in chromatin structure. For instance, there is an overall decrease in the 5methylcytosine content of cancer genomes that is reflected as hypermethylation in CpG
islands32. The consistently observed hypermethylation is due to a change in 5methylcytosine distributions rather than an overall increase in total amount of
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methylation. It has also been observed that large stretches of DNA can become
abnormally methylated in cancer.

Epigenetics of papillary thyroid cancer
Quantitative analysis of promoter hypermethylation in thyroid cancer has
involved RASSF1A, TSHR, RARβ2, DAPK, S100, p16, CDH1, CALCA, TIMP3, TGFβ, and GSTpi33. Hypermethylation of 2 or more markers (RASSF1A, TSHR, RARβ2,
DAPK, CDH1, TIMP3, TGF-β) was detectable in 25% of thyroid hyperplasias, 38% of
adenomas, 48% of thyroid cancers, and 100% of cell lines. Rank correlation analysis of
marker hypermethylation suggests that a subset of the markers were hypermethylated in
concert, which may represent a thyroid-specific regulatory process33. Additionally, a
positive correlation was observed between BRAF mutation and RARβ2, and a negative
correlation between BRAF mutation and RASSF1A33.
Investigation of DNA methylation in PTC has been predominantly restricted to
individual candidate tumor suppressor genes and genes known for their role in thyroid
function, using locus specific non-quantitative methods. BRAF, RASSFIA, TSHR,
ECAD, NIS-L, ATM, DAPK, SLC5A8, TIMP3, and RARβ2 have been analyzed for
DNA methylation. Promoter hypermethylation of TSHR, NIS-L, ATM, and ECAD has
been demonstrated in 34-59%34,35, 22%, 50%, and 56% of patients with papillary thyroid
cancer respectively35.
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Thyroid-stimulating hormone receptor (TSHR) and sodium iodide symporter (NIS)
TSHR stimulates several key steps in thyrocyte concentration of iodine, including
uptake by NIS and oxidation before incorporation into thyroglobulin by thyroid
peroxidase34. The methylation status of the NIS and TSHR promoter regions are
important because these genes are specific to the thyroid may play a role in the uptake of
iodine and normal cellular function35. Promoter hypermethylation resulting in decreased
expression of TSHR and NIS may result in a decreased ability to concentrate iodine,
rendering ablative doses of 131I ineffective35. Promoter hypermethylation of TSHR is
reported in 34-59%34,35 of patients with papillary thyroid cancer. NIS mRNA expression
has been shown to be decreased in thyroid cancers35,36, and this has been proposed to be
secondary to methylation of the promoter region35,32. The NIS-L region within the
promoter was shown to be hypermethylated in 22% (7/32) of patients with papillary
thyroid cancer35, but was not methylated in surrounding histologically benign tissue.

E-cadherin (ECAD)
E-cadherin complexes with catenins to promote Ca2+-dependent, homotypic cellto-cell adhesion and to establish normal epithelial tissue architecture37. Disruption of the
E-cadherin/catenin complex contributes to tumor metastasis, and decreased expression of
E-cadherin is observed in advanced stage, poorly differentiated carcinomas37. Promoter
hypermethylation has been demonstrated in multiple human cancers, including papillary
thyroid cancer in 56% (18/32) of patients35.
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Ataxia telangiectasia mutated (ATM)
ATM is a member of the phosphatidylinositol 3-kinase family of proteins that
respond to DNA damage by phosphorylating key substrates (p53, BRCA1) involved in
DNA repair and/or cell cycle control38-40. Hypermethylation of ATM promoter was
observed in 50% (16/32) of patients with papillary thyroid cancer analyzed35

Apical iodide transporter (AIT)
The thyroid apical iodide transporter AIT encoded by the SCL5A8 gene has been
defined as a sodium-coupled transporter of short-chain fatty acid. It is thought that AIT
may be involved in the passive transport of iodide from thyrocyte to the follicle
lumen41,42. Expression of SCL5A8 is decreased in thyroid cancers compared to other
iodide transporters41, and is expressed abundantly in colon cancer, functioning as a tumor
suppressor gene. Silencing of SLC5A8 occurs by promoter hypermethylation in about
50% of colon cancer cell lines and primary colon cancers. Decreased expression of
SLC5A8 observed in classical variant of papillary thyroid cancer is linked to
hypermethylation of exon 1 of the gene42.
Hypermethylation occurred in 33% (76/231) of PTC and was associated with
extrathyroidal invasion (40%) and multifocality (40%)43. This epigenetic event is thought
occur at a later stage in papillary thyroid cancer and specific of the classical variant,
therefore may be secondary to other genetic alterations occurring selectively in the tumor
type42. Indeed, SLC5A8 and BRAF discriminate the classical variant PTC, supporting the
argument. In addition, a strong association between low SLC5A8 expression and the
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presence of BRAF V600E42 or advanced clinicopathologic features43 suggests a link in
the progression to more aggressive papillary thyroid cancer.

The tissue inhibitor of metalloproteinase 3 (TIMP3)
TIMP3 is one of 4 tissue inhibitors of metalloproteinase thought to inhibit growth,
angiogenesis, invasion, and metastasis in several human cancers43,44. TIMP3 inhibits
vascular endothelial factor (VEGF)-mediated angiogenesis by blocking the binding of
VEGF to VEGF receptor-2, thereby inhibiting downstream signaling and angiogenesis44.
Promoter hypermethylation, and downregulation of TIMP3 expression is observed in
various human cancers43,45-47. Hypermethylation in PTC occurred in 53% of tumors
analyzed and was associated with extrathyroidal invasion (38%), lymph node metastasis
(43%), and multifocality (49%).

Death-associated protein kinase (DAPK)
DAPK is a calcium/calmodulin-dependent serine threonine kinase protein with a
pro-apoptotic, tumor suppressor function43,48. The DAPK gene is silenced by
hypermethylated in several human cancers43,49,50, including thyroid cancer, and its
expression has been shown to be a useful marker for cancer prognosis48. In addition to
aberrant DNA methylation, chromatin immunoprecipitation analysis demonstrated that
histone deacetylation of the 5' CpG island is involved in gastrointestinal malignancies49.
In papillary thyroid cancer, promoter hypermethylation of DAPK was demonstrated in
34% of PTC and was associated with tumor multifocality (51%)43.
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Retinoic acid receptor-β2 (RARβ2)
RARβ2 plays a central role in the regulation of epithelial cells growth and
tumorigenesis. Effects of retinoids are mediated by nuclear receptors, RAR-α, RAR-β,
and RAR-γ, RXR-α, RXR-β, and RXR-γ which form RXR-RAR heterodimers, which
bind to specific DNA sequences, called RAR elements. It is thought that decreased
expression of RARs may lead to resistance to retinoid effects51. Hypermethylation of
RARβ2 was demonstrated in 22% of papillary thyroid cancer, and was not associated
with any aggressive clinicopathologic features43.

Role of the Ras association domain family 1 isoform A (RASSF1A) in tumorigenesis
The Ras association domain family 1 isoform A (RASSF1A) is one of 3
transcripts of the RASSF1 gene on chromosome 3p21.3, derived from alternative
splicing52. Activation of this tumor suppressor gene is implicated in a number of sporadic
cancers. Rassf1A is thought to be an effector of RAS oncoproteins due to its RAS
association domain and is involved in regulation of cell cycle progression, apoptosis, and
microtubule stability.
Rassf1A functions as a negative regulator of cell proliferation as evidenced by
point mutations that inhibit tumor cell growth53-56. Rassf1A inhibits G1/S-phase
progression; re-expression of RASSF1A in lung and breast tumor-derived epithelial cells
results in growth arrest but not apoptosis55, which correlates with inhibition of cyclin D1
accumulation and subsequent loss of arrest at the RB family cell cycle restriction point,
allowing progression to S phase. Regulation of cyclin D1 accumulation by Rassf1A is
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independent of the cyclin D1 promoter and occurs through inhibition of mRNA
translation55.
Rassf1A is thought to play a role as a scaffolding protein that assembles effector
protein complexes. The death receptor stimulation results in the formation of a complex
between Rassf1A and a microtubule-association protein, MAP1. In the absence of
Rassf1A, MAP1 exists in an inactive closed conformation in inhibiting its interaction
with BAX, a member of the BCL2 family and an important component of apoptotic
machinery57,58. RassfF1A/MAP1 interaction is enhanced by activate K-Ras and is
required for conformational change in BAX, mitochondrial membrane insertion, and
maximal apoptosis in response to death receptor stimulation. Rassf1A and MAP1 are also
recruited to the TNF-alpha and TRAIL receptor apoptosis complexes in response to their
respective cognate ligands 59. Ectopic expression of Rassf1A enhances apoptosis in breast
cancer cells, and knockout by RNA interference in osteosarcoma and breast cancer cells
or by gene deletion in Rassf1a-null mouse embryonic fibroblasts specifically impairs
death receptor-dependent apoptosis59-61.
Another scaffolding role for Rassf1A involves stabilization of microtubules,
modulated by microtubule-associated proteins (MAPs). MAPs bind directly to tubulin,
and have also been shown to bind directly to Rassf1A60,62. This modulation of tubulin
dynamics may involve Rassf1A in cell motility. Overexpression of Rassf1A inhibits cell
migration, and Rassf1A knockout reduces cell-to-cell adhesion 61.
Rassf1A is a mitosis-specific inhibitor of the APC/C (anaphase-promoting
complex/cyclosome), a large multisubunit complex that collaborates with ubiquitinconjugating and ubiquitin-activating enzymes. Ubiquitin-activating enzymes catalyze the
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formation of polyubiquitin chains on its protein substrates that targets them for
proteasome degradation 60. The activity of APC/C is thought to be restricted to a specific
period in the cell cycle by the spatiotemporal regulation of mitosis by Rassf1A63.
Rassf1A interacts with Cdc20 and inhibits the APC, preventing degradation of cyclin A
and cyclin B until the spindle checkpoint becomes fully operational63.
The RASSF1A locus is genetically and epigenetically inactivated at high
frequency in a variety of solid tumors, conforming to Knudson’s two-hit hypothesis52,64.
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Figure 2. Pathways involving RASSF1A65. RASSF1A regulates mitosis, the cell cycle
and apoptosis in response to mitogenic or apoptotic stimuli. Direct interaction between
RASSF1A and microtubule-associated proteins localizes RASSF1A to the microtubules,
stabilizing them and, thereby, regulating mitosis. Repression of cyclins A and D1 by
RASSF1A results in cell cycle arrest and interactions with CNK1, MST1, Salvador and
MOAP1 may allow RASSF1A to modulate apoptosis.
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Table 1. Frequency of RASSF1A promoter hypermethylation in various tumor types65.
Tumor type

Frequency of hypermethylation

Lung (SCLC)

88%

Lung (NSCLC)

15 – 39%

Breast

81 – 95 %

Colorectal

20 – 52%

Prostate

99%

Cervical Adenocarcinoma

45%

Esophageal

34%

Gastric

44%

Renal

56 – 915

Hepatocellular

75%

Bladder

30 – 50%

Pancreatic

63%

Ovarian

26 – 30%

Nasopharyngeal

68%

Leukemia

0 – 15%

Neuroblastoma

83%

Thyroid

35 – 71%

Cholangiocarcinoma

67%

Ependymoma

36 – 86%

Glioma

54 – 57%

Hodgkin’s lymphoma

65%

Medulloblastoma

79%
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Retinoblastoma

59%

Testicular (Seminoma)

40%

Tesicular (Non-seminoma)

83%

Wilm’s tumor

54%

Rhabdomyosarcoma

61%

Pheochromocytoma

22%

Head and Neck

15 – 17%

Melanoma

41%
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HYPOTHESIS AND SPECIFIC AIMS

We hypothesize that characterization of the PTC “methylome” is likely to provide
insights into the molecular pathogenesis of PTC and lay the basis for prevention,
improved diagnosis, and classification of thyroid cancer and provide critical insights for
individualized medical and surgical treatment of these patients. We aim to
1. Characterize the PTC “methylome” in a discovery cohort of clinically wellcharacterized patients with both early (Stage I, T1 N0) and late stage PTC (Stage
III-IV, T3-4, N1b, M1) via quantitative whole genome DNA methylation analysis
in a “discovery set” of human PTC.
2. Analyze hypermethylation, gene silencing and function of selected genes
identified during the discovery phase in a larger “verification set” of human PTC.
This approach is likely to identify not only genes showing frequent alterations in
methylation patterns in PTC, but also genes and pathways altered in aggressive metastatic
PTC. Additional studies will be performed in a larger verification cohort of PTC as well
as functional, in vitro, studies of genes identified using this novel technology.
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MATERIAL AND METHODS

Subjects and Tissues (performed by thesis author)
Papillary thyroid carcinomas (n=50) were acquired from patients diagnosed and
surgically treated in the clinical routine at Yale-New Haven Hospital and clinical
characteristics are presented in Table 1. All tumors were carefully evaluated and
dissected by an experienced endocrine pathologist prior to use in the study and the
diagnosis of papillary thyroid carcinoma was unequivocal. Tissues were snap-frozen in
OCT using liquid nitrogen and stored in -80ºC. Informed consent and approval by the
institutional review board was obtained.

DNA and RNA isolation and Gene sequencing
High molecular weight genomic DNA was isolated from normal and neoplastic thyroid
tissue as previously described66 and gene sequencing was performed by the Yale Keck
Facility and analyzed using Genome Studio CodonCode Aligner.

Bisulfite modification of DNA (performed by thesis author)
Genomic DNA (500ng) was bisulphite modified using the EZ DNA Methylation kit
(Zymo Research, Orange, CA) according to the instructions from the manufacturer.
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Genome-wide DNA methylation profiling (performed by the principal investigator and
lab residents)
Bisulfite-modified DNA was analyzed using Infinium HumanMethylation27
BeadChip (Illumina, San Diego, CA). The Infinium HumanMethylation27 BeadChip
protocol comprises six steps (whole-genome amplification, fragmentation, hybridization,
washing, counterstaining and scanning)67, which were carried out at the Yale Center for
Genome Analysis at Yale University according to the manufacturer’s recommendation.
Details can be found at
http://www.illumina.com/downloads/InfMethylation_AppNote.pdf. The Infinium
HumanMethylation27 BeadChip is a novel genome-wide DNA methylation platform that
allows interrogation of 27,578 highly informative CpG sites per sample at singlenucleotide resolution68,69. The 12-sample Bead Chip features content derived from the
NCBI CCDS database (Genome Build 36) and is supplemented with more than 1,000
cancer-related genes68,69.

Methylation-specific Real-time PCR (MSP) analysis using SYBR Green (performed
by thesis author)
To verify the findings from the methylation arrays, selected genes were analyzed
using MS-PCR. Methylation-specific primers (table 2) were designed using the Methyl
Primer Express software. MethPrimer is based on Primer 3 software and searches an
input DNA sequence for potential CpGislands then designs MSP primers around those
sites. Semiquantitative PCR was performed on Bio-Rad systems Real-Time PCR systems
(Bio Rad Laboratories Inc. Hercules, CA, USA) using SYBR-Green PCR Master Mix
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(#4309155) and results were analyzed using StepOne Software v2.1 (Applied
Biosystems, Foster City, CA, USA). Commercial methylated, unmethylated, and
genomic DNA were used as MSP assay controls and for determining the cut-off for
hypermethylation. Percent methylation was calculated using the formula 100/[1+2^(Ct
Meth – Ct UnMeth)1]

Table 2. Primers used for methylation-specific real-time PCR analysis of gene expression
CpG Island

Forward primer

Reverse primer

RASSF1A-CpG#1-M

tttcgaagggtgaggtattc

ctcctatctcgaaacgctct

RASSF1A-CpG#1-UM

gggttttgaagggtgaggtattt

atactcctatctcaaaacactct

RASSF1A-CpG#2-M

agaaatacgggtattttcgc

acgaaactaaacgcgctc

RASSF1A-CpG#2-UM

tttagaaatatgggtatttttgt

aaacaaaactaaacacactct

CDKN2B/p15-CpG#1-M

attatagcggatagggggc

cgcctcgctctaacaaaat

CDKN2B/p15-CpG#1-UM gattatagtggatagggggt

ccacctcactctaacaaaat

CDKN2B/p15-CpG#2-M

cgcgtaaaatacacacct

gggttttagggtttcgtc

CDKN2B/p15-CpG#2-UM tggggttttagggttttgtt

tacacataaaatacacacct

1

Ct Meth and Ct UnMeth are the threshold cycles of methylated DNA and unmethylated
DNA from the MSP reaction.
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Quantitative RT-PCR analysis (performed by thesis author).
Complementary DNA (cDNA) was synthesized using 1 µg of total RNA and
iScript cDNA Synthesis Kit (Bio-Rad Laboratories Inc. Hercules, CA, USA). Primers
(table 3) were designed with Primer3Plus software or obtained from the NCI QPCR
primer database. Quantitative real-time PCR was performed on Bio-Rad systems RealTime PCR systems (Bio Rad Laboratories Inc. Hercules, CA, USA) using assays for
CDKN2B, RASSF1A, and GAPDH (All from Applied Biosystems, Foster City, CA).
Each cDNA sample was analyzed in triplicate. Standard curves were established for each
primer.

Table 3. Primers used for quantitative real-time PCR analysis of gene expression.
Gene

Forward primer

Reverse primer

RASSF1A

tgggagacacctgacctttc

tgggcaggtaaaaggaagtg

GAPDH

aaggtgaaggtcggagtcaa

aatgaaggggtcattgatgg

Statistical analysis (performed by the principal investigator, lab resident, and thesis
author). The BeadChip was scanned on the Illlumina iScan and the resulting files were
analyzed with the Beadstudio software (Version 3.2; Illumina). The output of the
Beadstudio analysis is a beta-value for each CpG site interrogated. This is a continuous
value between 0 and 1 where 0 indicates 0% methylation and 1 indicates 100%
methylation at a given CpG site. Therefore, this assay provides quantitative methylation
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measurement at the single CpG site level. The calculation of the beta-value is performed
as described67. Wilcoxon rank test, Student's unpaired t-test, and Fisher exact test were
used for statistical evaluation, with p<0.05 considered to be significant. All results are
expressed as mean ± SEM (standard error of the mean).
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RESULTS
Hierarchical clustering of genes with altered DNA methylation profiles in
papillary thyroid cancer did not show any relationship to age, gender, tumor size, lymph
node status, pathological or clinical TNM stage. However, a distinct DNA methylation
profile was noted in BRAF V600E PTC versus BRAF WT PTC, with 24 genes
displaying significant hypermethylation in BRAF V600E PTC versus BRAF WT
(p<0.005) (table 4). These included genes involved in transcriptional regulation and cell
cycle control such as CDKN2B/p15 and RASSF1A.
BRAF mutational status was determined by Sanger sequencing of papillary
thyroid tumors (figure 3). Twenty-five BRAF V600E PTC and BRAF WT PTC (table 5)
were selected for validation of the methylation profile of RASSF1 and analysis of its
gene expression. Tumors in the BRAF V600E cohort had the characteristic aggressive
phenotypes expected. Extrathyroidal extension, lymphovascular invasion, and lymph
node involvement was observed in 34% (p < 0.005), 22% (p < 0.005), and 48% (p <
0.0005) of tumors in the BRAF V600E cohort versus BRAF WT, respectively (table 5).
In addition, tumors in the BRAF V600E cohort presented at a higher AJCC stage. 59% of
BRAF V600E tumors were AJCC stage III-IV compared to 5% of the BRAF WT tumors
(p < 0.005). No significant difference in patient age or tumor size was observed.
Hypermethylation observed on the Infinium HumanMethylation27 BeadChip
methylation array was validated by methylation-specific quantitative PCR (MS-PCR).
One of two CpG islands (CpG#1) in the Rassf1A promoter was equally hypermethylated
in BRAF V600E PTC and BRAF WT PTC, with an average of 39% and 38%
respectively (figure 4). The second CpG island (CpG#2) was differentially methylated
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with an average of 73% and 8% (p<0.0005) methylation in BRAF V600E PTC and
BRAF WT PTC respectively (figure 5). Commercially available fully methylated, fully
unmethylated, and genomic DNA used as methylation controls, showed 96%, 1%, and
18% methylation of the Rassf1A promoter respectively (figure 6A).Ninety-two % (n=23)
of the BRAF V600E tumors were hypermethylated at CpG#2, compared to 12% (n=3) of
the BRAF WT tumors (figure 4A).
Two-step quantitative PCR was performed on RNA isolated from all tumors in
both cohorts. Gene expression was quantified and Rassf1A expression was normalized to
Gapdh. The efficiency of both primers were determined using a standard curve.
Normalized Rassf1A expression from each BRAF V600E tumor was compared to the
average expression in the BRAF WT cohort. Expression of Rassf1A was decreased 0.64fold in BRAF V600E PTC relative to expression in BRAF WT PTC (p<0.05).
Promoter hypermethylation of CDKN2B/p15 was also addressed. Two CpG
islands were assessed in the 5’-UTR and intron 1, and neither of these CpG islands were
hypermethylated in PTC. 99% and 0% methylation of the CDKN2B/p15 promoter was
seen in the methylated and unmethylated DNA controls, with some variation in the
genomic controls. The 5‘UTR CpG island showed 8% methylation while the CpG island
in intron 1 showed 34% methylation. The average methylation seen in the PTC cohorts at
both CpG islands was <2% (data not shown).

34

Table 4. 24 genes hypermethylated in BRAF V600E PTC versus BRAF WT PTC
BRAF
V600E

BRAF WT

PTC beta

PTC beta

Delta

Symbol

Name

value2

value

Beta

FAM113B

Hypothetical protein LOC91523

0.61

0.41

0.20

CD6

CD6 antigen

0.79

0.59

0.20

FLJ45909

Hypothetical protein LOC126432

0.61

0.41

0.20

Protein tyrosine phosphatase; non-receptor type 7
PTPN7

isoform 1

0.70

0.50

0.20

CDKN2B

Cyclin-dependent kinase inhibitor 2B

0.52

0.32

0.20

KLHL6

Kelch-like 6

0.62

0.41

0.20

Membrane-spanning 4-domains; subfamily A;
MS4A1

member 1

0.70

0.50

0.20

SEMA3B

Semaphorin 3B isoform 1 precursor

0.72

0.51

0.20

SLAMF8

B lymphocyte activator macrophage expressed

0.56

0.36

0.20

LGP2

Hypothetical protein LOC79132

0.33

0.12

0.20

CD5

CD5 antigen (p56-62)

0.80

0.59

0.21

RASSF1

Ras association domain family 1 isoform A

0.55

0.34

0.21

C16orf54

Chromosome 16 open reading frame 54

0.69

0.49

0.21

CDH5

Cadherin 5; type 2 preproprotein

0.64

0.43

0.21

ACY3

Aspartoacylase (aminocyclase) 3

0.53

0.33

0.21

LAPTM5

Lysosomal associated multispanning membrane

0.55

0.34

0.21

2

The beta-value or methylation index (MI) for each CpG site corresponds to the ratio of
the fluorescence signal from the methylated allele (C) to the sum of the fluorescent
signals of the methylated (C) and unmethylated (T) alleles75. The methylation status for
each detected CpG site ranges between 0.1 (completely unmethylated) to 1 (completely
methylated). Genes with a delta beta value ≥ 0.20 (difference between the methylation
status in BRAF V600E and BRAF WT) were considered differentially methylated.
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protein 5
LTA

Lymphotoxin alpha precursor

0.72

0.51

0.21

CREB3L3

cAMP responsive element binding protein 3-like 3

0.39

0.18

0.21

Protein phosphatase 1 regulatory inhibitor subunit
PPP1R16B

16B

0.58

0.37

0.21

LSP1

Lymphocyte-specific protein 1 isoform 1

0.74

0.53

0.21

ZBTB32

Testis zinc finger protein

0.81

0.60

0.21

LAT

Linker for activation of T cells isoform a

0.68

0.47

0.21

LIMD2

Hypothetical protein LOC80774

0.61

0.40

0.22

LY9

Lymphocyte antigen 9 isoform a

0.67

0.45

0.22

RASSF1

Ras association domain family 1 isoform A

0.54

0.32

0.22

VCY

Variable charge; Y-linked

0.73

0.51

0.22

CD79B

CD79B antigen isoform 1 precursor

0.63

0.41

0.22

FLJ33860

Hypothetical protein LOC284756

0.62

0.40

0.22

TMC8

EVIN2

0.76

0.53

0.23

C16orf54

Chromosome 16 open reading frame 54

0.78

0.55

0.23

C17orf62

Chromosome 17 open reading fram 62

0.64

0.40

0.23

RASSF1

Ras association domain family 1 isoform A

0.59

0.36

0.23

GPR114

G-protein coupled receptor 114

0.61

0.37

0.24

CD6

CD6 antigen

0.79

0.55

0.24

RASSF1

Ras association domain family 1 isoform A

0.61

0.37

0.24

C16orf24

Chromosome 16 open reading frame 24

0.56

0.31

0.26
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Figure 3. Sanger sequencing of the BRAF T1799A mutation. Left: Homozygous
T1799T sequence in BRAF WT PTC. Right: Heterozygous T1799A in BRAF
V600E PTC.
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Table 5. Twenty-five BRAF V600E PTC and BRAF WT PTC were used for validation
of the methylation profile of RASSF1 and analysis of its gene expression. *p < 0.05;
**p < 0.005; ***p < 0.0005

Clinicopathologic characteristics

BRAF V600E PTC

BRAF WT PTC

Age (yrs)

47

50

Tumor size (cm)

1.88

1.24

Classical variant (%)**

91

50

Follicular variant (%)**

9

50

Unifocal (%)

22

20

Multicfocal (%)*

65

40

Extrathyroidal extension (%)**

34

0

Lymphovascular invasion (%)**

22

0

Lymph node metastasis (%)***

48

0

AJCC Stage I – II (%)**

41

95

AJCC Stage III – IV (%)**

59

5
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Figure 4. CpG island #1 of the RASSF1A promoter was equally hypermethylated in
BRAF V600E PTC (mutated) and BRAF WT PTC (wildtype). A. An average of 38% and
39% methylation was observed in the mutated and wildtype samples respectively. B.
Methylation percentage of CpG island #1 for each individual tumor in the cohorts. Red
dots are BRAF V600E (mutated) PTC and blues dots are BRAF WT (wildtype) PTC.
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Figure 5. CpG #2 of the RASSF1A promoter was differentially methylated in BRAF
V600E PTC (mutated) and BRAF WT PTC (wildtype). A. An average of 73% and 8%
methylation was observed in the mutated and wildtype samples respectively. B. Shows
the methylation percentage of CpG #2 for each individual tumor in the cohorts. Red dots
are BRAF V600E (mutated) PTC and blues dots are BRAF WT (wildtype) PTC. ***p <
0.0005

40

Figure 6. 92% (n=23) of the BRAF V600E tumors were hypermethylated at this CpG
island, compared to 12% (n=3) of the BRAF WT tumors. A. Percentage of BRAF V600E
(mutated) PTC and BRAF WT (wildtype) PTC hypermethylated. B. Shows the
methylation percentages of commercially available control DNA. Meth = fully
methylated DNA; Unmeth = fully unmethylated DNA; Genomic = genomic DNA.
Hypermethylation defined as methylation >18% (observed in genomic DNA).
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Figure 7. Relative expression of RASSF1A was determined by quantitative QPCR
analysis, normalized to GAPDH. A. RASSF1A expression was decreased in BRAF
V600E PTC relative to expression in BRAF WT PTC (p<0.05). B. RASSF1A expression
of individual samples in the BRAF V600E PTC cohort relative to the mean expression of
the BRAF WT PTC cohort.
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DISCUSSION

The DNA methylation profile of PTC correlates with BRAF mutational status,
underscoring its importance in PTC development. Twenty-four genes were significantly
hypermethylated in BRAF V600E versus BRAF WT PTC, including genes involved in
transcriptional control and cell cycle regulation. One of two CpG islands in the
RASSF1A promoter was hypermethylated in 92% of BRAF V600E PTC, with an
average of 72% methylation, compared to 12% of BRAF WT PTC (8% average
methylation). Hypermethylation of this CpG island appears to correlate with reduced
RASSF1A mRNA levels in BRAF V600E PTC. No other clinical or pathological
characteristics correlated with the DNA methylation profile of PTC on the genome-wide
DNA methylation array performed.
The molecular mechanism of the more aggressive phenotype of BRAF V600E
PTC may be related to aberrant DNA methylation of genes involved in transcriptional
and cell cycle control. Functional studies assessing the effect of this hypermethylation on
RASSF1A gene expression may further determine a cause-effect relationship. In addition
to the mRNA analysis performed, protein expression analysis using
immunohistochemistry and western blot analysis on PTC tissue would detect any changes
in RASSF1A expression in BRAF V600E PTC compared to expression in wildtype
tumors. Furthermore, assessing the effect of azanucleoside, a demethylating agent, on
RASSF1A gene expression in PTC cell cultures may further determine a cause-effect
relation, and would be critical in assessing the possibility of clinically applying a
demethylating agent to treatment of aggressive, BRAF V600E PTC.
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With improved diagnostic techniques, endocrine tumors are identified much more
frequently than in the past. For instance, benign parathyroid tumors occurs in as many as
2.3% of postmenopausal women70, and primary hyperaldosteronism may be the cause of
hypertension in as many as 4.8% of all patients with elevated blood pressure71. The
molecular genetics of rare inherited endocrine tumor susceptibility syndromes, such as
multiple endocrine neoplasia (MEN) type 1 and 2, familial pheochromocytoma
syndromes, Carney Complex, and Beckwith-Wiedemann syndrome have all contributed
to our understanding of endocrine tumor development72,73. Among different tumor types,
there exist common pathways that lead to tumorigenesis, such as inactivation of the
MEN1 tumor suppressor and activation of the RET proto-oncogene. As in other cancers,
it is believed that the vast majority of genetic changes are somatic, i.e. tumor specific
mutations acquired during tumor progression74.
Epigenetic mechanisms, especially aberrant DNA methylation, very likely play an
important role in papillary thyroid tumorigenesis. Genome-wide DNA methylation
studies in PTC provide a powerful tool to identify disease-causing genes. Additionally,
unbiased, systematic analyses of tumor methylomes are likely to identify signaling
pathways of importance in cancer development, in general. Analyzing epigenetic
alterations in papillary thyroid cancer would help to characterize pathogenesis and may
play a critical role in tumor classification and diagnosis. It has recently been shown that
there differences in global methylation profiles between prognostic subsets of chronic
lymphocytic leukemia (CLL)75. The specific silencing of unmethylated tumor suppressor
genes was seen in the unmutated IGHV subgroup of CLL, implying a critical role for
epigenetic changes during leukemogenesis. Interestingly, patients with immunoglobulin
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heavy-chain variable gene (IGHV) unmutated CLL have worse prognoses compared to
CLL patients with mutated IGHV genes75.
These studies may also pave the way for the application of epigenetic
therapeutics, by targeted reversal of gene silencing. Azanucleoside drugs are
demethylating agents that are currently approved for treatment of myelodyspastic
syndrome19,72. These function as DNA methyltransferase enzymes, require incorporation
into DNA to be effective, and affect the differentiated state. Other nucleoside DNA
methylation inhibitors include 5-fluoro-2’-deoxycytidine and zebulamine76 which are in
development. Histone deacetylases77,78 and histone methyltransferases are another
reasonable option for therapeutics. The histone deacetylase SAHA is currently approved
by the FDA for treatment of T cell lymphoma79.
Just as multiple epigenetic events may act in concert to affect a single-cell
pathway, it is most likely that epigenetic therapy will involve using multiple drugs that
individually affect epigenetic silencing but have synergistic effects. Proposed strategies
for the FDA approved epigenetic drugs are as single therapies or in combination as
primary or secondary treatment after neo-adjuvant chemotherapy. Lack of specificity
may not pose a problem since DNMT inhibitors act only on dividing cells. The drugs
preferentially activate genes that have become abnormally silenced in cancer80.
Moreover, the chromatin structure associated with a pathologically silenced gene may be
more susceptible to reactivation than the highly compacted state induced by physiological
silencing19.
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